Awards

BostonGene has received numerous awards that reflect our dedication and expertise, underscoring our commitment to advancing precision medicine.

Stevie® Awards for Technology Excellence 2024: Technology Breakthrough of the Year

Frost & Sullivan's Best Practices Award 2024: Enabling Technology Leadership

Frost & Sullivan’s 2025 North American Enabling Technology Leadership Award

GlobalData: Leading Innovator in AI-Driven Drug Repurposing

Cancer Cell: State-of-the-Art Technology in Cancer Research and Oncology

Fierce Life Sciences Innovation Awards 2023: Data Analytics/Business Intelligence

Year

Winner

Pinnacle Awards 2026: Diamond Winner for AI-Driven Decision-Making

Winner

Frost & Sullivan Best Practices Awards 2026: Global AI-Driven Multimodal Oncology Platforms Company of the Year

Recognition

Symbol 1000: The Global Awards Index for 2026

Winner

Boston Life Sciences Times Vanguard Awards 2026: Innovator of the Year

Winner

Frost & Sullivan Best Practices Awards 2025: Global Technology Innovation Leadership in AI-Driven Precision Oncology Solutions

Winner

AI Breakthrough Awards 2025: Overall Immunology Company of the Year

Winner

Gold Stevie® Awards for Biomarker Discovery Platform 2025: Technical Innovation of the Year

Winner

Gold Stevie® Awards for Target Analysis Solution 2025: Technology Breakthrough of the Year

Winner

Silver Stevie® Awards for End-to-End Drug Repurposing Solutions 2025: New Product of the Year

Winner

Silver Stevie® Awards for Biomarker Discovery Platform 2025: Technical Innovation of the Year

Winner

Silver Stevie® Awards For Target Analysis Solution 2025: Technology Breakthrough of the Year

Winner

Pinnacle Awards 2025: Platinum Winner for AI Research Innovation

Testimonials

Through BostonGene, we are utilizing multiparametric discovery and big data analytics to uncover and validate biomarkers of therapeutic response.

Funda Meric-Bernstam, MD

Chair of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center

We look forward to using BostonGene’s technology to facilitate our work in mechanisms of cancer neoantigen recognition.

Gerald Linette, MD, PhD

Clinical Director of the Parker Institute for Cancer Immunotherapy, University of Pennsylvania

Together, we are working to identify novel biomarkers and develop next-generation therapies fora true personalized approach to cancer care.

David Ting, MD

Associate Clinical Director of Innovation, Massachusetts General Hospital

A tumor ‘‘personality’’ test: the BostonGene Tumor Portrait serves as a roadmap to guide treatment decision-making.

Christina Curtis, PhD, MSc

Director of Artificial Intelligence and Cancer Genomics and Breast Cancer Translational Research Stanford University

Through this collaboration we look forward to utilizing data and AI to gain more insights into the biology and mechanisms of investigational therapies at the earliest stages. These data will help us to better understand their potential in certain patient populations and ultimately help advance oncology medicines for patients who need them.

PK Morrow, MD

Head, Oncology Therapeutic Area Unit, Takeda

BostonGene's integrated analytic and AI capabilities will provide us with crucial insights towards developing breakthrough cancer treatments.

Stephen Slocum, PhD

Director of Drug Development, LigoChem

Collaborating with BostonGene allows us to apply advanced omnimodal analytics to real-world clinical challenges. By integrating genomic, transcriptomic and immune data into a unified platform, we can identify the right patients for the right trials, uncover novel biomarkers...

Ola Landgren, MD, PhD

Director of the Sylvester Myeloma Institute and professor of medicine with the Miller School of Medicine